Acute myeloid leukemia (AML) is often classified as an oncologic emergency leading to rapid evaluation and treatment in the hospital. Previous studies reported that time from diagnosis to treatment (TDT) had no impact on outcomes, but these data were limited to patients already intensively pretreated and/or not living in the US. A new study in adults with newly diagnosed AML, presented at ASH, comes to new conclusions.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Pain and autism
Hurdles to pain treatment for autistic patients
- Pathophysiological mechanisms and therapeutic perspectives
Metabolic syndrome in patients with schizophrenia
- Hand eczema: from diagnosis to treatment
Implementing sustainable, stage-appropriate measures
- Cystic fibrosis
Small spray – big footprint
- From symptom to diagnosis
Abdominal pain – Gastric outlet stenosis
- When the bones become more fragile: “Case Finding”
Fracture risk reduction in osteoporosis
- Biologics for plaque psoriasis
What increases the chance of a sustained remission?
- Findings from the ALS Symposium 2024 in Montreal